Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

CHD5 is down-regulated through promoter hypermethylation in gastric cancer
BMC: Journal of Biomedical Science, 10/26/09

Wang X et al. – In this study, the involvement of CHD5 in gastric cancer was investigated , the second most common cancer worldwide. CHD5 was a TSG epigenetically down-regulated in gastric cancer.

Methods

CHD5 expression in panel of gastric cancer cells determined by quantitative RT-PCR
Methylation of CHD5 evaluated by methylation specific PCR and bisulfite genome sequencing
Effect of CHD5 on growth of gastric cancer cells tested by colony formation assay

Results

CHD5 expression down-regulated in all of gastric cancer cell lines used (100%, 7/7) and significantly restored after pharmacological demethylation
Methylation of CHD5 promoter detected in all of 7 gastric cancer cell lines and in majority of primary gastric carcinoma tissues examined (73%, 11/15)
Ectopic expression of CHD5 in gastric cancer cells led to significant growth inhibition

<< Previous
STK15 F31I polymorphism is associated with breast cancer risk: a...

Next >>
Effect of allopurinol versus urate oxidase on methotrexate...